fenfluramine has been researched along with Hypertension in 30 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects)." | 9.07 | Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. ( Detry, JM; Kolanowski, J; Vanbutsele, R; Younis, LT, 1992) |
| "Dexfenfluramine and fenfluramine greatly increase the risk of developing pulmonary hypertension (PHT)." | 7.70 | Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. ( Archer, SL; Dall'ava-Santucci, J; Dinh-Xuan, AT; Djaballah, K; Fartoukh, M; Humbert, M; Mercier, JC; Simonneau, G; Weir, KE, 1998) |
| "Fenfluramine is a recently introduced anorexigenic drug for the treatment of obesity." | 7.65 | Fenfluramine-associated hypertension. ( Mabadeje, AF, 1975) |
| " Adverse events were usually moderate and transient, occurring at the beginning of treatment." | 6.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects)." | 5.07 | Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. ( Detry, JM; Kolanowski, J; Vanbutsele, R; Younis, LT, 1992) |
| " Several people attended a Chinese herbalist for weight loss advice and were sold 'herbal' preparations that contained fenfluramine, a drug which was withdrawn from sale in the West in 1997 after its use was linked to primary pulmonary hypertension and valvular heart disease." | 3.71 | Risks associated with herbal slimming remedies. ( Corns, C; Metcalfe, K, 2002) |
| "Nineteen participants, all of whom had hypertension, were being treated with fenfluramine or dexfenfluramine (5 on these agents alone, 14 also with phentermine)." | 3.71 | Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. ( Arnett, DK; Bella, JN; de Simone, G; Devereux, RB; Hopkins, PN; Kitzman, DW; Liu, JE; Morgan, D; Oberman, A; Palmieri, V; Roman, MJ, 2002) |
| "Dexfenfluramine and fenfluramine greatly increase the risk of developing pulmonary hypertension (PHT)." | 3.70 | Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. ( Archer, SL; Dall'ava-Santucci, J; Dinh-Xuan, AT; Djaballah, K; Fartoukh, M; Humbert, M; Mercier, JC; Simonneau, G; Weir, KE, 1998) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Hydrochlorothiazide, a drug which is often initially prescribed for mild to moderate hypertension, failed to lower blood pressures in 9 of 43 patients but concomitantly elevated plasma norepinephrine (NE) levels in all patients with hypertension." | 3.66 | Fenfluramine potentiation of antihypertensive effects of thiazides. ( Coleman, MD; Kopin, IJ; Lake, CR; Ziegler, MG, 1980) |
| "Fenfluramine is a recently introduced anorexigenic drug for the treatment of obesity." | 3.65 | Fenfluramine-associated hypertension. ( Mabadeje, AF, 1975) |
| "Benfluorex treatment lowered diastolic and systolic blood pressures and improved glucose tolerance in both age groups." | 2.68 | Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. ( Beer, NA; Beer, RM; Colombo, C; Jakubowicz, DJ; Nestler, JE, 1995) |
| " Adverse events were usually moderate and transient, occurring at the beginning of treatment." | 2.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "The syndrome is characterized by insulin insensitivity and an increased control of metabolism by cortisol." | 2.38 | Neuroendocrine regulation and obesity. ( Brindley, DN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (40.00) | 18.7374 |
| 1990's | 12 (40.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nau, JY | 2 |
| Corns, C | 1 |
| Metcalfe, K | 1 |
| Stocker, SD | 1 |
| Muldoon, MF | 1 |
| Sved, AF | 1 |
| Etienne, N | 1 |
| Schaerlinger, B | 1 |
| Jaffré, F | 1 |
| Maroteaux, L | 1 |
| Fuller, RW | 1 |
| Yen, TT | 1 |
| Stamm, NB | 1 |
| Lake, CR | 1 |
| Ziegler, MG | 1 |
| Coleman, MD | 1 |
| Kopin, IJ | 1 |
| Genné, D | 1 |
| De Torrenté, A | 1 |
| Humair, L | 1 |
| Nestler, JE | 1 |
| Beer, NA | 1 |
| Jakubowicz, DJ | 1 |
| Colombo, C | 1 |
| Beer, RM | 1 |
| Berlin, I | 1 |
| Puech, AJ | 1 |
| Monego, ET | 1 |
| Peixoto, Mdo R | 1 |
| Jardim, PC | 1 |
| Sousa, AL | 1 |
| Braga, VL | 1 |
| Moura, MF | 1 |
| Sukkari, SR | 1 |
| Enzi, G | 1 |
| Archer, SL | 1 |
| Djaballah, K | 1 |
| Humbert, M | 1 |
| Weir, KE | 1 |
| Fartoukh, M | 1 |
| Dall'ava-Santucci, J | 1 |
| Mercier, JC | 1 |
| Simonneau, G | 1 |
| Dinh-Xuan, AT | 1 |
| Derby, LE | 1 |
| Myers, MW | 1 |
| Jick, H | 1 |
| Greenway, FL | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Palmieri, V | 1 |
| Arnett, DK | 1 |
| Roman, MJ | 1 |
| Liu, JE | 1 |
| Bella, JN | 1 |
| Oberman, A | 1 |
| Kitzman, DW | 1 |
| Hopkins, PN | 1 |
| Morgan, D | 1 |
| de Simone, G | 1 |
| Devereux, RB | 1 |
| Von Mühlendahl, KE | 1 |
| Krienke, EG | 1 |
| Scott, ME | 1 |
| Nelson, PG | 1 |
| Mabadeje, AF | 2 |
| Brindley, DN | 1 |
| Rowland, NE | 1 |
| Fregly, MJ | 1 |
| Poortman, CM | 1 |
| Li, H | 1 |
| Kolanowski, J | 1 |
| Younis, LT | 1 |
| Vanbutsele, R | 1 |
| Detry, JM | 1 |
| Mroczek, WJ | 1 |
| Lee, WR | 1 |
| Finnerty, FA | 1 |
| Hoyer, I | 1 |
| Van Zwieten, PA | 1 |
| Wilton, TD | 1 |
| Follows, OJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00005267] | 3,604 participants (Actual) | Observational | 1995-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fenfluramine and Hypertension
| Article | Year |
|---|---|
[The 5-HT2B receptor: a main cardio-pulmonary target of serotonin].
Topics: Adult; Animals; Cardiomyopathy, Dilated; Cell Survival; Fenfluramine; Fetal Heart; Genes, Lethal; Ge | 2004 |
Neuroendocrine regulation and obesity.
Topics: Animals; Diabetes Complications; Endocrine Glands; Fenfluramine; Humans; Hydrocortisone; Hyperlipide | 1992 |
8 trials available for fenfluramine and Hypertension
| Article | Year |
|---|---|
Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men.
Topics: Aged; Aging; Androgens; Blood Glucose; Blood Pressure; Dehydroepiandrosterone; Dehydroepiandrosteron | 1995 |
[Different therapies in the treatment of obesity in hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Body Weight; Diet, Fat-Restricted; Double-Blind Method | 1996 |
[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Appetite Depressants; Diabetes Mellitus; Diabetes Mel | 1997 |
Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients.
Topics: Adult; Blood Pressure; Body Weight; Catecholamines; Double-Blind Method; Exercise; Female; Fenfluram | 1992 |
Circulatory effects of fenfluramine in obese hypertensive patients.
Topics: Blood Pressure; Body Weight; Cardiac Output; Clinical Trials as Topic; Female; Fenfluramine; Heart R | 1974 |
Fenfluramine--another appetite suppressant.
Topics: Central Nervous System; Clinical Trials as Topic; Fenfluramine; Humans; Hypertension; Placebos | 1973 |
A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Diethylpropion; Female; | 1971 |
Hypotensive effect of fenfluramine in the treatment of obesity.
Topics: Adult; Aged; Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Hypertension; Male; Middl | 1971 |
20 other studies available for fenfluramine and Hypertension
| Article | Year |
|---|---|
Topics: Appetite Depressants; Blood Pressure; Fenfluramine; Genomics; Humans; Hypertension; Motion Pictures; | 2016 |
[What were the indications for the Mediator in 1979?].
Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases | 2011 |
Risks associated with herbal slimming remedies.
Topics: Abdominal Pain; Adult; Chromatography, Gas; Drug Interactions; Drugs, Chinese Herbal; Female; Fenflu | 2002 |
Blunted fenfluramine-evoked prolactin secretion in hypertensive rats.
Topics: Acute Disease; Adrenergic alpha-Agonists; Animals; Blood Pressure; Chronic Disease; Fenfluramine; Hy | 2003 |
Lowering of blood pressure by direct- and indirect-acting serotonin agonists in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Fenfluramine; Hypertension; Male; Metergo | 1981 |
Fenfluramine potentiation of antihypertensive effects of thiazides.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Drug Synergism; Drug Therapy, Combination; Fen | 1980 |
[Voluntary poisoning with dexfenfluramine (Isomeride)].
Topics: Adolescent; Drug Overdose; Female; Fenfluramine; Humans; Hypertension; Iatrogenic Disease; Poisoning | 1994 |
Is it dexfenfluramine or weight loss that reduces blood pressure and noradrenergic activity in obese patients?
Topics: Blood Pressure; Body Weight; Fenfluramine; Humans; Hypertension; Norepinephrine; Obesity | 1993 |
Weighing benefits and risks of drug to treat obesity.
Topics: Appetite Depressants; Conflict of Interest; Fenfluramine; Humans; Hypertension; Obesity; Risk Assess | 1997 |
Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
Topics: Adult; Aged; Angina Pectoris; Appetite Depressants; Case-Control Studies; Dexfenfluramine; Disease S | 1998 |
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
Topics: Aged; Appetite Depressants; Body Mass Index; Case-Control Studies; Cerebrovascular Disorders; Cohort | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Drug Combinations; Female; Fenflu | 2002 |
Fenfluramine poisoning.
Topics: Adolescent; Adult; Central Nervous System Diseases; Child; Child, Preschool; Female; Fenfluramine; H | 1979 |
Fenfluramine in the treatment of hypertensive patients with refractory obesity.
Topics: Female; Fenfluramine; Humans; Hypertension; Male; Middle Aged; Obesity; Placebos; Pregnancy | 1975 |
Fenfluramine-associated hypertension.
Topics: Adult; Blood Pressure; Female; Fenfluramine; Humans; Hypertension; Male; Middle Aged; Obesity; Time | 1975 |
Effect of chronic administration of dexfenfluramine on blood pressure in salt-sensitive rats.
Topics: Animals; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule | 1992 |
The central hypotensive action of amphetamine, ephedrine, phentermine, chlorphentermine and fenfluramine.
Topics: Amphetamine; Animals; Appetite Depressants; Blood Pressure; Cats; Chlorphentermine; Depression, Chem | 1972 |
Proceedings: Fenfluramine-induced hypertension.
Topics: Female; Fenfluramine; Humans; Hypertension; Male; Obesity | 1974 |
Letter: Fenfluramine in complicated obesity.
Topics: Diabetes Complications; Diabetes Mellitus; Female; Fenfluramine; Humans; Hypertension; Male; Middle | 1974 |